KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Capital Leases: 2017-2024

Historic Capital Leases for Moderna (MRNA) over the last 8 years, with Dec 2024 value amounting to $39.0 million.

  • Moderna's Capital Leases fell 95.84% to $26.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.0 million, marking a year-over-year decrease of 95.84%. This contributed to the annual value of $39.0 million for FY2024, which is 93.22% down from last year.
  • Per Moderna's latest filing, its Capital Leases stood at $39.0 million for FY2024, which was down 93.22% from $575.0 million recorded in FY2023.
  • Moderna's 5-year Capital Leases high stood at $912.0 million for FY2022, and its period low was $39.0 million during FY2024.
  • In the last 3 years, Moderna's Capital Leases had a median value of $575.0 million in 2023 and averaged $508.7 million.
  • In the last 5 years, Moderna's Capital Leases skyrocketed by 444.55% in 2021 and then tumbled by 93.22% in 2024.
  • Yearly analysis of 5 years shows Moderna's Capital Leases stood at $110.0 million in 2020, then skyrocketed by 444.55% to $599.0 million in 2021, then soared by 52.25% to $912.0 million in 2022, then slumped by 36.95% to $575.0 million in 2023, then plummeted by 93.22% to $39.0 million in 2024.